[HTML][HTML] Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis
N Gagelmann, F Passamonti, C Wolschke… - …, 2022 - ncbi.nlm.nih.gov
Vaccines against SARS-CoV-2 have shown remarkable efficacy and thus constitute an
important preventive option against coronavirus disease 2019 (COVID-19), especially in …
important preventive option against coronavirus disease 2019 (COVID-19), especially in …
Immunogenicity of COVID-19 vaccines in patients with hematologic malignancies: a systematic review and meta-analysis
JSK Teh, J Coussement, ZCF Neoh… - Blood …, 2022 - ashpublications.org
The objectives of this study were to assess the immunogenicity and safety of COVID-19
vaccines in patients with hematologic malignancies. A systematic review and meta-analysis …
vaccines in patients with hematologic malignancies. A systematic review and meta-analysis …
The third dose of mRNA SARS-CoV-2 vaccines enhances the spike-specific antibody and memory B cell response in myelofibrosis patients
F Fiorino, A Ciabattini, A Sicuranza, G Pastore… - Frontiers in …, 2022 - frontiersin.org
Vaccination against SARS-CoV-2 using mRNA-based vaccines has been highly
recommended for fragile subjects, including myelofibrosis patients (MF). Available data on …
recommended for fragile subjects, including myelofibrosis patients (MF). Available data on …
A systematic review and meta-analysis of immune response against first and second doses of SARS-CoV-2 vaccines in adult patients with hematological …
M Noori, S Azizi, FA Varaki, SA Nejadghaderi… - International …, 2022 - Elsevier
Background Cancer patients particularly those with hematological malignancies are at
higher risk of affecting by severe coronavirus disease 2019 (COVID-19). Due to the …
higher risk of affecting by severe coronavirus disease 2019 (COVID-19). Due to the …
Adult patients with cancer have impaired humoral responses to complete and booster COVID-19 vaccination, especially those with hematologic cancer on active …
E Liatsou, I Ntanasis-Stathopoulos, S Lykos… - Cancers, 2023 - mdpi.com
Simple Summary Taking into consideration the high risk of patients with cancer for severe
COVID-19 infection, prioritization has been given to primary prevention with both primary …
COVID-19 infection, prioritization has been given to primary prevention with both primary …
The slower antibody response in myelofibrosis patients after two doses of mRNA SARS-CoV-2 vaccine calls for a third dose
F Fiorino, A Sicuranza, A Ciabattini, A Santoni… - Biomedicines, 2021 - mdpi.com
Immunization with mRNA SARS-CoV-2 vaccines has been highly recommended and
prioritized in fragile subjects, including patients with myelofibrosis (MF). Available data on …
prioritized in fragile subjects, including patients with myelofibrosis (MF). Available data on …
Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with …
GA Palumbo, D Cambria, E La Spina… - Frontiers in …, 2023 - frontiersin.org
Patients affected by myelofibrosis (MF) or polycythemia vera (PV) and treated with ruxolitinib
are at high risk for severe coronavirus disease 2019. Now a vaccine against the virus SARS …
are at high risk for severe coronavirus disease 2019. Now a vaccine against the virus SARS …
Successful SARS-CoV-2 mRNA vaccination program in allogeneic hematopoietic stem cell transplant recipients—a retrospective single-center analysis
A Nikoloudis, IJ Neumann, V Buxhofer-Ausch… - Vaccines, 2023 - mdpi.com
(1) Background: mRNA COVID-19 vaccines are effective but show varied efficacy in
immunocompromised patients, including allogeneic hematopoietic stem cell transplant …
immunocompromised patients, including allogeneic hematopoietic stem cell transplant …
Impaired humoral and T cell response to vaccination against SARS-CoV-2 in chronic myeloproliferative neoplasm patients treated with ruxolitinib
P Harrington, KJ Doores, J Saunders, M de Lord… - Blood Cancer …, 2022 - nature.com
Inferior outcomes have been observed with SARS-CoV-2 infection in patients with chronic
myeloid neoplasms, emphasising the importance of development of robust immunity in this …
myeloid neoplasms, emphasising the importance of development of robust immunity in this …
[HTML][HTML] Vaccinations in hematological patients in the era of target therapies: Lesson learnt from SARS-CoV-2
B Fattizzo, N Rampi, W Barcellini - Blood Reviews, 2023 - Elsevier
Novel targeting agents for hematologic diseases often exert on-or off-target
immunomodulatory effects, possibly impacting on response to anti-SARS-CoV-2 …
immunomodulatory effects, possibly impacting on response to anti-SARS-CoV-2 …